TY - JOUR
T1 - (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer
AU - Rosas, Juan E.
AU - Aguado-Barrera, Miguel
AU - Azria, David
AU - Briers, Erik
AU - Elliott, Rebecca
AU - Farcy-Jacquet, Marie-Pierre
AU - Giraldo, Alexandra
AU - Gutierrez-Enriquez, Sara
AU - Rancati, Tiziana
AU - Rattay, Tim
AU - Reyes, Victoria
AU - Rosenstein, Barry
AU - De Ruysscher, Dirk
AU - Sperk, Elena
AU - Stobart, Hilary
AU - Talbot, Christopher
AU - Vega, Ana
AU - Taboada-Valladares, Begona
AU - Veldeman, Liv
AU - Ward, Tim
AU - Webb, Adam
AU - West, Catharine
AU - Chang-Claude, Jenny
AU - Seibold, Petra
AU - REQUITE consortium
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Fatigue is common in breast-cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long-term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI-20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post-RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI-20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P < .05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI-20 fatigue dimensions (ORGeneralFatigue = 3.81, P < .001). From latent trajectory analysis, patients with a combination of factors such as pain, insomnia, depression, younger age and endocrine therapy had a particularly high risk of developing early and persistent high fatigue years after treatment. Our results confirmed the multidimensional nature of fatigue and will help clinicians identify breast cancer patients at higher risk of having persistent/late fatigue so that tailored interventions can be delivered.
AB - Fatigue is common in breast-cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long-term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI-20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post-RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI-20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P < .05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI-20 fatigue dimensions (ORGeneralFatigue = 3.81, P < .001). From latent trajectory analysis, patients with a combination of factors such as pain, insomnia, depression, younger age and endocrine therapy had a particularly high risk of developing early and persistent high fatigue years after treatment. Our results confirmed the multidimensional nature of fatigue and will help clinicians identify breast cancer patients at higher risk of having persistent/late fatigue so that tailored interventions can be delivered.
KW - breast cancer
KW - determinants
KW - fatigue
KW - longitudinal trajectories
KW - radiotherapy
KW - QUALITY-OF-LIFE
KW - EUROPEAN-ORGANIZATION
KW - RADIATION-THERAPY
KW - PREVALENCE
KW - SURVIVORS
KW - WOMEN
KW - INSTRUMENT
KW - PREDICTORS
KW - DEPRESSION
KW - SYMPTOMS
U2 - 10.1002/ijc.34640
DO - 10.1002/ijc.34640
M3 - Article
C2 - 37403702
SN - 0020-7136
VL - 153
SP - 1579
EP - 1591
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 9
ER -